Impact of Sex and BMI on Diabetes Treatment Response

Introduction to Personalized Medicine

A recent study conducted in the UK indicates that the sex and body mass index (BMI) of patients significantly influence their response to certain second-line diabetes treatments. Personalized medicine is a medical approach that tailors medical decisions to individual patient characteristics. While this concept often brings to mind advanced biological assays and genetic testing, the recent diabetes study demonstrates that not all personalized medicine guidelines require sophisticated technology.

Current Diabetes Treatment Practices

Most patients diagnosed with type 2 diabetes initially receive metformin as their primary medication. However, when additional treatments become necessary, there are limited guidelines available to assist physicians in selecting the appropriate second-line drug. Treatment decisions are frequently based on data from large-scale studies, focusing primarily on average glycemic responses and overall side effects.

Study Overview

A report published in the BMJ outlines a UK study aimed at identifying patient characteristics that could aid physicians in their decision-making process regarding diabetes treatment. The full research findings appear in the journal Diabetes Care. The study analyzed data from 22,379 diabetic patients who had undergone treatment with either sulfonylurea or thiazolidinediones (TZDs) for a minimum of five years, drawing information from both clinical trials and general practice.

Key Findings on Treatment Responses

The researchers discovered that both sex and BMI significantly affected how patients responded to these diabetes medications. Non-obese men exhibited better glycemic responses when treated with sulfonylurea compared to TZDs. In contrast, obese women showed superior glycemic responses with TZDs over sulfonylureas. Additionally, side effects varied by sex and BMI, with obese women facing a higher risk of weight gain and fluid retention when prescribed TZDs. Importantly, the study found that sex and BMI did not increase the risk of hypoglycemia associated with these medications.

Implications for Treatment Guidelines

The authors of the study propose that sex and BMI should be considered when selecting appropriate second-line diabetes treatments, as these factors can lead to improved glycemic responses. Implementing these straightforward criteria, which incur no additional costs, could enhance treatment guidelines and provide valuable support to overburdened public health systems.

References

Dennis JM, Henley WE et al. Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. Diabetes Care. 2018 Sep;41(9):1844-1853. doi: 10.2337/dc18-0344. Epub 2018 Aug 2.

Wise J. Diabetes: simple patient characteristics should help inform choice of second line drug, study finds. BMJ. 2018; 362 doi: https://doi.org/10.1136/bmj.k3368 (Published 03 August 2018)